Macquarie Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Macquarie Group’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,207	Closed	-$273	–	1784
2024 Q4	$273	Buy	+16,207	New	+$311K	﹤0.01%	1612
2024 Q2	–	Sell	-160,000	Closed	-$2.37M	–	2088
2024 Q1	$2.37M	Hold	160,000	–	–	﹤0.01%	1173
2023 Q4	$2.32M	Hold	160,000	–	–	﹤0.01%	1179
2023 Q3	$1.73M	Hold	160,000	–	–	﹤0.01%	1208
2023 Q2	$2.06M	Hold	160,000	–	–	﹤0.01%	1176
2023 Q1	$2.11M	Hold	160,000	–	–	﹤0.01%	1148
2022 Q4	$2.4M	Hold	160,000	–	–	﹤0.01%	1154
2022 Q3	$1.89M	Sell	160,000 -325	-0.2%	-$4.4K	﹤0.01%	1248
2022 Q2	$1.81M	Hold	160,325	–	–	﹤0.01%	1329
2022 Q1	$4.79K	Hold	160,325	–	–	﹤0.01%	1126
2021 Q4	$4.25M	Hold	160,325	–	–	﹤0.01%	1155
2021 Q3	$5.82M	Hold	160,325	–	–	0.01%	1071
2021 Q2	$6.96M	Hold	160,325	–	–	0.01%	1034
2021 Q1	$5.48M	Sell	160,325 -154	-0.1%	-$6.1K	0.01%	888
2020 Q4	$5.62M	Hold	160,479	–	–	0.01%	857
2020 Q3	$3.85M	Hold	160,479	–	–	0.01%	887
2020 Q2	$2.94M	Buy	160,479 +479	+0.3%	+$8.62K	0.01%	913
2020 Q1	$2.5M	Hold	160,000	–	–	0.01%	866
2019 Q4	$3.42M	Hold	160,000	–	–	﹤0.01%	898
2019 Q3	$2.99M	Hold	160,000	–	–	0.01%	905
2019 Q2	$4.18M	Hold	160,000	–	–	0.01%	820
2019 Q1	$4.11M	Hold	160,000	–	–	0.01%	828
2018 Q4	$3.68M	Hold	160,000	–	–	0.01%	825
2018 Q3	$5.14M	Hold	160,000	–	–	0.01%	781
2018 Q2	$4.53M	Buy	160,000 +70,000	+78%	+$2.49M	0.01%	798
2018 Q1	$3.19M	Buy	90,000 +11,591	+15%	+$464K	0.01%	863
2017 Q4	$3.04M	Buy	78,409 +5,000	+7%	+$190K	0.01%	909
2017 Q3	$1.86M	Buy	73,409 +9,909	+16%	+$241K	﹤0.01%	1007
2017 Q2	$1.73M	Buy	63,500 +10,279	+19%	+$281K	﹤0.01%	1009
2017 Q1	$1.76M	Buy	+53,221	New	+$1.36M	﹤0.01%	1005

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's RIGL Position: Q1 2025 in Review

Macquarie Group sold out of Rigel Pharmaceuticals (RIGL) in Q1 2025, closing a stake of 16,207 shares — an estimated $273 sold.

Macquarie Group first reported a position in RIGL in Q1 2017 and held it in 30 quarters. The position peaked at $6.96M in Q2 2021. 123 funds tracked by Wall St. Rank hold RIGL as of Q1 2025.

Macquarie Group reported no remaining Rigel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Macquarie Group sold 16,207 Rigel Pharmaceuticals shares in Q1 2025, an estimated $273.
Macquarie Group first reported a position in Rigel Pharmaceuticals in Q1 2017 and held it in 30 quarters.
Macquarie Group's Rigel Pharmaceuticals position peaked at $6.96M in Q2 2021.
123 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2025.

Based on Macquarie Group's 13F filing for Q1 2025, filed 15 May 2025.